Canaccord Genuity analyst Kyle Rose said Allergan's (NYSE: AGN) CE Mark issues ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE